Physician profile
Patricia Stringer
NPI 1033115423
$15,690.26
in general payments reported to CMS, 2019-2025
50 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,201 · 2020: $1,798 · 2021: $1,953 · 2022: $2,454 · 2023: $2,503 · 2024: $2,488 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,224 · Education: $60.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,223.94 |
| Education | $60.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,776.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,520.37 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,359.48 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $1,285.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,187.62 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,051.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,038.69 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $949.85 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $557.82 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $542.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $499.18 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $420.58 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $375.07 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $332.58 | 2019-2024 | Veozah, Myrbetriq |
| Lexicon Pharmaceuticals, INC. | $221.45 | 2024 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.